BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18:862-867. [PMID: 30249386 DOI: 10.1016/j.pan.2018.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhou X. Meta-analysis of the diagnostic performance of serum carbohydrate antigen 19-9 for the detection of gallbladder cancer. Int J Biol Markers 2022;:17246008211068866. [PMID: 34982019 DOI: 10.1177/17246008211068866] [Reference Citation Analysis]
2 Lee JE, Choi SY, Lee MH, Lim S, Min JH, Hwang JA, Lee S, Kim JH. Differentiating between benign and malignant ampullary strictures: a prediction model using a nomogram based on CT imaging and clinical findings. Eur Radiol 2022. [PMID: 35585200 DOI: 10.1007/s00330-022-08856-7] [Reference Citation Analysis]
3 Nista EC, Schepis T, Candelli M, Giuli L, Pignataro G, Franceschi F, Gasbarrini A, Ojetti V. Humoral Predictors of Malignancy in IPMN: A Review of the Literature. Int J Mol Sci 2021;22:12839. [PMID: 34884643 DOI: 10.3390/ijms222312839] [Reference Citation Analysis]
4 Lang SA, Bednarsch J, Joechle K, Amygdalos I, Czigany Z, Heij L, Ulmer TF, Neumann UP. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Rev Gastroenterol Hepatol 2021;15:497-510. [PMID: 33970740 DOI: 10.1080/17474124.2021.1912591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Anderson MA, Bhati CS, Ganeshan D, Itani M. Hepatobiliary mucinous cystic neoplasms and mimics. Abdom Radiol (NY) 2021. [PMID: 34687327 DOI: 10.1007/s00261-021-03303-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lahoud RM, O'Shea A, El-Mouhayyar C, Atre ID, Eurboonyanun K, Harisinghani M. Tumour markers and their utility in imaging of abdominal and pelvic malignancies. Clin Radiol 2021;76:99-107. [PMID: 32861463 DOI: 10.1016/j.crad.2020.07.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
8 Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, Murrone A, Bianchi F, Amantini C, Giulietti M, Ricci G, Principato G, Santoni G, Berardi R, Cascinu S. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS One 2019;14:e0215990. [PMID: 31048929 DOI: 10.1371/journal.pone.0215990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
9 Xu H, Hua J, Meng Q, Wang X, Xu J, Wang W, Zhang B, Liu J, Liang C, Yu X, Shi S. Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. Front Oncol 2021;11:640820. [PMID: 33718237 DOI: 10.3389/fonc.2021.640820] [Reference Citation Analysis]
10 Mocan LP, Ilieș M, Melincovici CS, Spârchez M, Crăciun R, Nenu I, Horhat A, Tefas C, Spârchez Z, Iuga CA, Mocan T, Mihu CM. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol 2022; 28(15): 1508-1525 [DOI: 10.3748/wjg.v28.i15.1508] [Reference Citation Analysis]
11 Ni Y, Zhang Y, Xiang K, Zhao P, Pan G, Peng Y, Shi J, Zhou L, Mao L, Luo D. Axillary lymph node metastasis from papillary thyroid carcinoma with elevated CA 19-9 and CA 242 levels: a case report and literature review. Gland Surg 2021;10:1147-53. [PMID: 33842258 DOI: 10.21037/gs-20-815] [Reference Citation Analysis]
12 Prodromidou A, Pandraklakis A, Loutradis D, Haidopoulos D. Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? Cureus. 2019;11:e6342. [PMID: 31938630 DOI: 10.7759/cureus.6342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Metra BM, Guglielmo FF, Halegoua-DeMarzio DL, Civan JM, Mitchell DG. Beyond the Liver Function Tests: A Radiologist's Guide to the Liver Blood Tests. Radiographics 2021;:210137. [PMID: 34797734 DOI: 10.1148/rg.210137] [Reference Citation Analysis]
14 Kamel F, Eltarhoni K, Nisar P, Soloviev M. Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection. Cancers 2022;14:1889. [DOI: 10.3390/cancers14081889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Reference Citation Analysis]
16 Vitello DJ, Bentrem DJ. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. J Surg Oncol 2021;123:1449-59. [PMID: 33831249 DOI: 10.1002/jso.26369] [Reference Citation Analysis]
17 Bai M, Fu W, Su G, Cao J, Gao L, Huang C, Ma H, Zhang J, Yue P, Bai B, Lin Y, Meng W, Li X. The role of extracellular vesicles in cholangiocarcinoma. Cancer Cell Int 2020;20. [DOI: 10.1186/s12935-020-01526-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg 2020; 12(12): 468-490 [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
19 Kato S, Honda K. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers (Basel) 2020;12:E1965. [PMID: 32707720 DOI: 10.3390/cancers12071965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Jang SI, Cho JH, Kim SY, Hong IY, Park JS, Lee HS, Park G, Kim JK, Lee HK, Lee DK. Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14:853. [PMID: 35159120 DOI: 10.3390/cancers14030853] [Reference Citation Analysis]
21 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Restrepo DJ, Moreau C, Edelson CV, Dev A, Saligram S, Sayana H, Patel SN. Improving Diagnostic Yield in Indeterminate Biliary Strictures. Clin Liver Dis 2022;26:69-80. [PMID: 34802664 DOI: 10.1016/j.cld.2021.08.007] [Reference Citation Analysis]
23 Boyd LNC, Ali M, Kam L, Puik JR, Rodrigues SMF, Zwart ES, Daams F, Zonderhuis BM, Meijer LL, Le Large TYS, Giovannetti E, van Laarhoven HWM, Kazemier G. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach. Cancers (Basel) 2022;14:344. [PMID: 35053506 DOI: 10.3390/cancers14020344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Manne A, Esnakula A, Abushahin L, Tsung A. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:3059. [PMID: 34205412 DOI: 10.3390/cancers13123059] [Reference Citation Analysis]
25 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]